<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; BIIB</title>
	<atom:link href="http://www.stockbloghub.com/tag/biib/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BIIB) Biogen Analyst Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609</link>
		<comments>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609#comments</comments>
		<pubDate>Sat, 21 Jan 2012 20:38:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90609</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort, expansion into new markets and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continues to see an increase in patients despite carrying a “black box” warning for the risk of progressive multifocal leukoencephalopathy (PML) and other cautionary language. Tysabri posted $1.2 billion in sales in 2010. Tysabri’s launch in new markets like India, Brazil, Argentina, the Middle East and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam States Preclinical Data</title>
		<link>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523</link>
		<comments>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523#comments</comments>
		<pubDate>Tue, 03 Jan 2012 19:15:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89523</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington&#8217;s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington&#8217;s disease. Further, ALN-HTT was well tolerated in these studies. ALN-HTT is being developed in collaboration with Medtronic, Inc. (MDT) and the CHDI Foundation. Alnylam expects to file an investigational new drug application (IND) application for the candidate in 2012. Approval of the IND by the US Food &#38; Drug Administration (FDA) will allow the candidate to enter early stage clinical trials. Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish</title>
		<link>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197</link>
		<comments>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88197</guid>
		<description><![CDATA[We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam’s third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss 36 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. The loss was, however, wider than the year-ago loss of $0.23 per share. Revenues for the reported quarter fell 24.9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898</link>
		<comments>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87898</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data from the study is expected in mid-2012. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals (CBST) has the opt-in right to collaborate with the company in future for the lung transplant indication. Kyowa Hakko Kirin has opt-in rights for the candidate in Asia. Alnylam’s RNAi technology is potentially revolutionary. Alnylam is utilizing this know-how for selectively turning off the activity of certain genes to build a pipeline of drug candidates to treat a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data</title>
		<link>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547</link>
		<comments>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:32:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87547</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the treatment of ATTR. Overall, the candidate has proved to be well tolerated with no serious adverse events observed in the study. We believe the encouraging data further highlights the potential of RNAi as a new class of therapeutics. This is the first time an RNAi has silenced a disease-causing gene in clinical trials. ALN-TTR01 is part of Alnylam’s core product strategy, Alnylam 5&#215;15, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BXP) Boston Properties Beats Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2011/10/26/bxp-boston-properties-beats-earnings-estimates/85947</link>
		<comments>http://www.stockbloghub.com/2011/10/26/bxp-boston-properties-beats-earnings-estimates/85947#comments</comments>
		<pubDate>Wed, 26 Oct 2011 16:17:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Office]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Boston Properties Inc.]]></category>
		<category><![CDATA[BXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85947</guid>
		<description><![CDATA[Boston Properties Inc. (BXP), one of the leading real estate investment trusts (REITs), reported third quarter 2011 FFO (funds from operations) of $190.3 million or $1.28 per share, compared with $150.8 million or $1.07 per share in the year-earlier quarter. Fund from operations, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. The reported FFO for the quarter surpassed the Zacks Consensus Estimate by 4 cents. The increase in third quarter 2011 FFO was primarily due to strong rental income, which improved 17.3% during the quarter on a year-over-year basis. Total revenue of the company during the reported quarter were $452.4 million, compared with $386.4 million in the year-ago quarter. The quarterly revenues were well ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/26/bxp-boston-properties-beats-earnings-estimates/85947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757#comments</comments>
		<pubDate>Thu, 06 Oct 2011 23:38:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84757</guid>
		<description><![CDATA[Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates a situation where the cholesterol levels in the blood are higher than normal. The randomized, single-blind, placebo-controlled, single-ascending dose study intends to evaluate the safety and tolerability of the candidate in patients suffering from high low-density lipoprotein cholesterol (LDLc or “bad” cholesterol). Moreover, the clinical activity of ALN-PCS is also expected to be assessed through the study on the basis of measurements of plasma PCSK9 protein and serum LDLc. Results from the study, which is being conducted in the UK, are expected by year end. ALN-PCS is a part of Alnylam’s core product strategy &#8211; 5&#215;15 introduced ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gains &#8211; Earnings Miss Estimates</title>
		<link>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628</link>
		<comments>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628#comments</comments>
		<pubDate>Thu, 04 Aug 2011 15:47:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80628</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s earnings. Revenues Quarterly revenues shot up 52.4% to $65.3 million, driven primarily by strong Ampyra sales. However, revenues marginally missed the Zacks Consensus Estimate of $67 million. Second quarter revenues comprised $62.9 million (up 55.3%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $51.8 million, reflecting a year-over-year increase of 85%. Ampyra, aimed at improving walking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MS) Merck KGaA Seeks Rebif Extension</title>
		<link>http://www.stockbloghub.com/2011/07/07/ms-merck-kgaa-seeks-rebif-extension/78547</link>
		<comments>http://www.stockbloghub.com/2011/07/07/ms-merck-kgaa-seeks-rebif-extension/78547#comments</comments>
		<pubDate>Thu, 07 Jul 2011 17:04:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78547</guid>
		<description><![CDATA[Merck KGaA (MKGAF) recently filed a marketing application with the European Medicines Agency (EMA) in its endeavor to expand the label of Rebif, its multiple sclerosis (MS) therapy. The company is seeking approval for Rebif to treat patients who have experienced a single demyelinating event (an early symptom of the disease) and who stand a high risk of developing MS. Merck KGaA’s application was supported by data from the REFLEX study, which met the primary endpoint of delaying the time to conversion to McDonald MS (2005) – a criterion for the diagnosis of MS. The study evaluated patients who suffered from a demyelinating event such as optic neuritis, myelopathy or brainstem syndrome and had magnetic resonance imaging brain scans consistent with early signs of MS. Rebif is currently available worldwide ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/ms-merck-kgaa-seeks-rebif-extension/78547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315</link>
		<comments>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:03:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77315</guid>
		<description><![CDATA[We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer. The company’s lead pipeline candidate, pixantrone, is being developed for the treatment of hematologic malignancies and solid tumors. In December 2010, Cell Therapeutics filed an appeal against the decision of the FDA in April 2010 to deny approval to pixantrone for the treatment of relapsed, aggressive non-Hodgkin&#8217;s lymphoma, or NHL, in patients who have not responded to other treatment options. The approval was denied due to concerns that the late stage trial PIX301 (which formed the basis of the NDA filing) had not sufficiently proved the effectiveness of the drug. The FDA asked Cell Therapeutics to conduct an additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug</title>
		<link>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278</link>
		<comments>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:03:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77278</guid>
		<description><![CDATA[Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to market cladribine as a treatment for relapsing-remitting multiple sclerosis (MS). This decision comes after Merck KGaA’s discussions with the FDA at the end-of-review meeting related to the new drug application (NDA) for cladribine. Merck KGaA believes that data from the ongoing clinical trials will not be sufficient to address the FDA’s requirements for approval. The company is of the view that to gain US and EU approval, it will have to conduct a new clinical trial program that would take several years to complete. Cladribine is currently marketed as Movectro in Australia and Russia for the treatment of relapsing-remitting MS. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(APOG) Company News for June 23, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238</link>
		<comments>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238#comments</comments>
		<pubDate>Thu, 23 Jun 2011 16:06:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[General Building Materials]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[APOG]]></category>
		<category><![CDATA[Apogee Enterprises Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FDX]]></category>
		<category><![CDATA[FedEx Corporation]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Jabil Circuit Inc.]]></category>
		<category><![CDATA[JBL]]></category>
		<category><![CDATA[RBN]]></category>
		<category><![CDATA[Robbins & Myers Inc]]></category>
		<category><![CDATA[SCBT]]></category>
		<category><![CDATA[SCBT Financial Corporation]]></category>
		<category><![CDATA[Western Refining Inc.]]></category>
		<category><![CDATA[WNR]]></category>
		<category><![CDATA[XRAY]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77238</guid>
		<description><![CDATA[•    Shares of Robbins &#38; Myers, Inc. (NYSE:RBN) jumped 8.77% on strong fiscal third-quarter profits. The energy equipment supplier said strong customer demand and the recent acquisition of oilfield services has helped the company&#8217;s increase its profits •    Shares of Jabil Circuit (NYSE:JBL) gained 3.18% to close at $19.45 after the company posted earnings that doubled from the previous year. The company also initiated buyback of $200 million of stock •    Apogee Enterprises (NASDAQ:APOG) reported a Q1 loss of $0.08 per share. Revenues increased 7.2% year-over-year to $153.3 million, surpassing the Zacks Consensus Estimate of $147.0 million •    Share prices of shipping service giant FedEx (NYSE:FDX) rose 2.59% after the company posted earnings that came in above analysts’ expectations. The company also projected robust earnings growth for 2012 •    DENTSPLY ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri</title>
		<link>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127</link>
		<comments>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127#comments</comments>
		<pubDate>Wed, 22 Jun 2011 19:16:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77127</guid>
		<description><![CDATA[Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus antibody status as an additional factor that could help stratify the risk of progressive multifocal leukoencephalopathy (PML) occurring in patients treated with Tysabri. The EC’s decision for the label update does not surprise us as in April 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) had backed the inclusion of the additional risk in the Tysabri label. The updated label in the EU will provide patients (treated with Tysabri) as well as doctors additional assistance in identifying the risk of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Posts Positive Pixantrone Data</title>
		<link>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854</link>
		<comments>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:21:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76854</guid>
		<description><![CDATA[Cell Therapeutics Inc. (CTIC) recently announced that data from an early stage study of its lead pipeline candidate, pixantrone, for an additional indication, was published in Cancer, an online journal. The study (n=28) tested the efficacy and safety of pixantrone as a combination therapy with fludarabine, dexamethasone and Biogen/Roche’s (BIIB/RHHBY) Rituxan (FPD-R) for the treatment of relapsed or refractory indolent non-hodgkin’s lymphoma (INHL). In this study pixantrone was substituted for mitoxantrone in the FPD-R regimen compared to the standard FND-R regimen. The data revealed that pixantrone in combination with fludarabine, dexamethasone and Rituxan was highly active in patients with relapsed or refractory INHL and produced complete response (CR) in 63% of patients. The overall response rate (ORR) was 89%. The response lasted for 40 months in the longest responding patient ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFAM) Company News for June 21, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924</link>
		<comments>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924#comments</comments>
		<pubDate>Tue, 21 Jun 2011 15:28:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Home Health Care]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AFAM]]></category>
		<category><![CDATA[Agrium Inc.]]></category>
		<category><![CDATA[AGU]]></category>
		<category><![CDATA[Almost Family Inc.]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Carpenter Technology Corporation]]></category>
		<category><![CDATA[CRS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Harbin Electric Inc.]]></category>
		<category><![CDATA[HRBN]]></category>
		<category><![CDATA[PETM]]></category>
		<category><![CDATA[Petsmart Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SWKS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76924</guid>
		<description><![CDATA[•    Manufacturer and distributors of stainless steel and titanium products, Carpenter Technology (NYSE:CRS)  has concluded a merger agreement with Latrobe Specialty Metals as per which the former will acquire the latter in a deal worth around $558 million •    Shares of PNC Financial Services (NYSE:PNC) fell marginally, by 1.96% after the company announced it was acquiring the U.S. retail banking operations of the Royal Bank of Canada for $3.45 billion •    Chinese electric-motor manufacturer Harbin Electric (NASDAQ:HRBN) has entered into a definitive agreement as per which it will be acquired by a company owned by Chairman and Chief Executive Tianfu Yang for $744 million •    Share prices of Agrium Inc. (NYSE:AGU) jumped 4.05% to close at $82.98 after the company increased its outlook for second quarter earnings. Agrium said strong ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA</title>
		<link>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603</link>
		<comments>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:50:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76603</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application (NDA) for its lead pipeline candidate pixantrone. Pixantrone has been developed for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. The company is also looking for accelerated approval of the NDA based on data from the PIX301 study. The meeting follows the early May decision of the Office of New Drugs (OND) of the FDA allowing the company to re-submit the NDA for pixantrone for review without the need for an additional trial. The OND recommended Cell Therapeutics to conduct an additional independent radiologic review utilizing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra</title>
		<link>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214</link>
		<comments>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:45:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76214</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12). The analysis comprised data from a phase II trial and two phase III trials of Ampyra. These data were a part of Acorda’s new drug application (NDA) submission to the US Food and Drug Administration (FDA) for the approval of the drug. At the CMSC meeting, another set of study data on Ampyra called – UTI (urinary tract infection) Incidence among MS Patients Treated with Dalfampridine 10 mg Twice Daily – was also presented. As the name suggests, the study evaluated the incidence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermesto Buy Elan Unit for $960 Million</title>
		<link>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637</link>
		<comments>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637#comments</comments>
		<pubDate>Mon, 09 May 2011 22:55:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73637</guid>
		<description><![CDATA[Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately $960 million. The merged entity will be known as Alkermes plc and will be headquartered in Dublin, Ireland. The deal, expected to boost Alkermes’ cash earnings immediately following its closure, has been cleared by the board of directors of both companies. Morgan Stanley &#38; Co. (MS) and HSBC (HBC) have agreed to finance up to $450 million of the deal through term loans to Alkermes. Per the terms of the deal, Alkermes will make a cash payment of $500 million apart from giving Elan 31.9 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532</link>
		<comments>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532#comments</comments>
		<pubDate>Sun, 08 May 2011 15:50:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73532</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating expenses resulted in a loss during the quarter. Quarterly Details Quarterly revenues saw a whopping 245.3% increase to reach $61.3 million, with Ampyra sales exceeding expectations. However, revenues missed the Zacks Consensus Estimate of $65 million. Fourth quarter revenues comprised $58.9 million (up 282.9%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $46.8 million. Ampyra, aimed at improving walking speed in multiple sclerosis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs</title>
		<link>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234</link>
		<comments>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:42:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72234</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher multiple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Report Beats The Street</title>
		<link>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122</link>
		<comments>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122#comments</comments>
		<pubDate>Sat, 23 Apr 2011 15:25:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72122</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher mutliple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen&#8217;s Oral Multiple Sclerosis Drug Impresses</title>
		<link>http://www.stockbloghub.com/2011/04/13/biib-biogens-oral-multiple-sclerosis-drug-impresses/71500</link>
		<comments>http://www.stockbloghub.com/2011/04/13/biib-biogens-oral-multiple-sclerosis-drug-impresses/71500#comments</comments>
		<pubDate>Thu, 14 Apr 2011 02:14:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71500</guid>
		<description><![CDATA[Biogen (BIIB) received a boost recently with the company presenting promising top-line data on its oral multiple sclerosis candidate, BG-12. The company presented positive results on the use of BG-12 as a monotherapy in patients suffering from relapsing-remitting multiple sclerosis (RRMS). DEFINE Data Data from the phase III global, randomized, double-blind, placebo-controlled, dose-comparison DEFINE study showed that BG-12 (240 mg dosed twice/thrice daily) brought about a statistically significant reduction in the proportion of patients experiencing a relapse in disease at two years. Both doses of BG-12 met the secondary endpoints as well which included a statistically significant reduction in annualized relapse rate, the number of new or newly enlarging T2 hyperintense lesions, new gadolinium-enhancing (Gd+) lesions, and the rate of disability progression. Biogen also reported that the candidate’s safety and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/biib-biogens-oral-multiple-sclerosis-drug-impresses/71500/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Company News for April 12, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/12/aa-company-news-for-april-12-2011-corporate-summary/71270</link>
		<comments>http://www.stockbloghub.com/2011/04/12/aa-company-news-for-april-12-2011-corporate-summary/71270#comments</comments>
		<pubDate>Tue, 12 Apr 2011 17:57:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Community Health Systems Inc.]]></category>
		<category><![CDATA[CYH]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[FLO]]></category>
		<category><![CDATA[Flowers Foods Inc.]]></category>
		<category><![CDATA[GLBC]]></category>
		<category><![CDATA[Global Crossing Limited]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Level 3 Communications Inc.]]></category>
		<category><![CDATA[LVLT]]></category>
		<category><![CDATA[Tasty Baking Company]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[TSTY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71270</guid>
		<description><![CDATA[• Level 3 Communications (NASDAQ:LVLT) and Global Crossing Limited (NASDAQ:GLBC) have entered into a agreement under which Level 3 will acquire Global Crossing in a stock-for-stock transaction • Endo Pharmaceuticals&#8217; (NASDAQ:ENDP) said that it would buy urological medical device supplier American Medical Systems (NASDAQ:AMMD) for about $2.6 billion • Alcoa (NYSE:AA) reported Q1 EPS of $0.28, ex-items, ahead of the Zacks Consensus Estimate of $0.27 per share. Revenues for the quarter rose 22% year-over-year to $6.0 billion, lower than the Zacks Consensus Estimate of $6.112 billion • Share prices of Molycorp, Inc. (NYSE:MCP) increased 5% after JP Morgan (NYSE:JPM) raised its target price to $90 from $74 • Credit Suisse upgraded BHP Billiton (NYSE:BHP) to ‘Outperform’ from ‘Neutral’ rating. Share prices of BHP Billiton gained 1.34% to close at $102.68 • Flowers Food Inc. (NYSE:FLO) said ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/12/aa-company-news-for-april-12-2011-corporate-summary/71270/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Ramps Up Earnings &#8211; Settles Disputes</title>
		<link>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805</link>
		<comments>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:02:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67805</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a penny short of the Zacks Consensus Estimate of 21 cents. For full year 2010, PDL reported earnings per share of 97 cents, down from $1.06 per share in 2009 but ahead of the Zacks Consensus Estimate of 90 cents. Full year 2010 revenues of $345 million were well above the prior-year figure of $318.2 million. Revenues also beat the Zacks Consensus Estimate of $343 million. 2009 revenues included royalties from MedImmune, a subsidiary of AstraZeneca (AZN), on sales of Synagis, which PDL no longer receives. Excluding this revenue, sales were up 30% over the prior year. Quarterly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Reports Fourth Quarter Earnings Beat</title>
		<link>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288</link>
		<comments>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288#comments</comments>
		<pubDate>Tue, 22 Feb 2011 17:50:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67288</guid>
		<description><![CDATA[The Medicines Company (MDCO) reported a fourth-quarter profit of 27 cents per share, including the impact of stock-based compensation expense. Fourth quarter profit exceeded the Zacks Consensus Estimate of 24 cents and the year-ago loss of 57 cents. Performance was boosted by higher revenues and lower operating expenses. Revenues, up 17.3% at $119.6 million, surpassed the Zacks Consensus Estimate of $111 million. Full-year earnings came in at $1.15 per share, in-line with the Zacks Consensus Estimate and well above the year-ago loss of 46 cents. Full year revenues increased 8.3% to $437.6 million, well above the Zacks Consensus Estimate of $429 million. The Quarter in Detail Angiomax continued to see strong demand during the quarter with US sales increasing 16.3% to $112 million. US sales benefited from continued demand in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Quarterly Earnings Report Beats by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2011/02/01/biib-biogen-quarterly-earnings-report-beats-by-a-wide-margin/66175</link>
		<comments>http://www.stockbloghub.com/2011/02/01/biib-biogen-quarterly-earnings-report-beats-by-a-wide-margin/66175#comments</comments>
		<pubDate>Wed, 02 Feb 2011 05:06:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66175</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported fourth-quarter earnings per share of $1.41, well above the Zacks Consensus Estimate of $1.23 and the year-earlier figure of $1.18. Excluding the impact of stock-based compensation expense, fourth quarter 2010 earnings came in at $1.42 per share. Full year earnings came in at $5.03 per share, beating the Zacks Consensus Estimate of $4.89 and the year-ago earnings of $4.03. Excluding the impact of stock-based compensation expense, 2010 earnings came in at $5.15 per share. Performance was boosted by higher revenues and lower share count. Fourth quarter revenues increased 8.2% to $1.22 billion, with Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks Consensus Estimate of $1.17 billion. Full year revenues increased 7.7% to $4.72 billion, above the Zacks Consensus Estimate of $4.67 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/01/biib-biogen-quarterly-earnings-report-beats-by-a-wide-margin/66175/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reports Smaller Third Quarter Loss Than Expected</title>
		<link>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805</link>
		<comments>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805#comments</comments>
		<pubDate>Fri, 26 Nov 2010 04:33:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58805</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc.’s (ALNY) third quarter loss of 23 cents per share was narrower than the Zacks Consensus Estimate of 39 cents but wider than the year-ago loss of 22 cents per share. The wider loss in the third quarter of 2010 was primarily attributable to the higher spend on research and development during the quarter. Revenues for the reported quarter climbed 14% to $27.7 million, above the Zacks Consensus Estimate of $26 million. Revenues were inclusive of $14 million from the company’s alliance with Roche (RHHBY), $5.6 million from Alnylam‘s partnership with Takeda Pharmaceuticals, in addition to $8.1 million of expense reimbursement and amortization revenues from Novartis (NVS), the National Institutes of Health, Cubist Pharmaceuticals Inc. (CBST) and Biogen Idec Inc. (BIIB) among others. Research and development (R&#38;D) costs ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Meets Earnings Forecast &#8211; Beats Revenue Forecast</title>
		<link>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524</link>
		<comments>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524#comments</comments>
		<pubDate>Thu, 18 Nov 2010 05:07:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59524</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) posted third quarter earnings of 25 cents per share, in line with the Zacks Consensus Estimate, but below the year-ago figure of 29 cents. Earnings declined in the quarter, despite the increase in revenue, due to higher selling and general expenses. Quarterly Details Third quarter revenue of $86.4 million was higher than the Zacks Consensus Estimate of $84 million and about 21% above the year-ago revenue. The top-line increase resulted from higher 2Q10 sales of Roche’s (RHHBY) Avastin, Herceptin, and Lucentis, and Biogen/Elan’s (BIIB/ELN) Tysabri, on which PDL BioPharma received royalties in 3Q10. Revenue was, however, in line with the company’s guidance of $86 million provided in September 2010. Quarterly general and administrative expenses increased from $5.3 million in the year-earlier quarter to $11.1 million in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Earnings Well Above on Lower Costs</title>
		<link>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953</link>
		<comments>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953#comments</comments>
		<pubDate>Wed, 03 Nov 2010 15:34:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56953</guid>
		<description><![CDATA[The Medicines Company (MDCO) reported a third-quarter profit of 40 cents per share Incorporatedluding the impact of stock-based compensation expense. Third quarter profit was well above the Zacks Consensus Estimate of 24 cents and the year-ago loss of 6 cents. Performance was boosted by higher revenues and lower operating expenses. Revenues, although up 6.9% at $105.7 million, fell short of the Zacks Consensus Estimate of $110 million. The Quarter in Detail Angiomax continued to see strong demand during the quarter. Angiomax sales in the US increased 9% to $100.2 million with Angiomax box sales increasing 14% from the year-ago period. EU sales increased 38% to $4 million mainly due to strong growth in countries like Italy, Switzerland, Spain, France, Scandinavia, and the United Kingdom. RoW sales, however, declined 42% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELN) Elan Quarterly Report Matches Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476</link>
		<comments>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476#comments</comments>
		<pubDate>Wed, 03 Nov 2010 15:12:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57476</guid>
		<description><![CDATA[Elan Corporation plc (ELN) reported loss per share of 7 cents for the third quarter of 2010, in line with the Zacks Consensus Estimate but way below the year-ago earnings of 11 cents per share. The year-ago quarter saw Elan recording a divestment gain of $107.7 million, which is primarily the reason for the substantial year-over-year decline in earnings. On an adjusted basis, the company reported a loss of 5 cents per share, an improvement from a loss of 11 cents per share in the third quarter of 2009. Revenues Quarterly revenues declined 2% year over year to $281.4 million and also missed the Zacks Consensus Estimate of $298 million. Elan operates through two segments – BioNeurology and Elan Drug Technologies (EDT). Revenues from the BioNeurology segment went up 0.2% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Beats Earnings Forecast by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2010/10/26/biib-biogen-beats-earnings-forecast-by-a-wide-margin/56648</link>
		<comments>http://www.stockbloghub.com/2010/10/26/biib-biogen-beats-earnings-forecast-by-a-wide-margin/56648#comments</comments>
		<pubDate>Tue, 26 Oct 2010 15:55:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56648</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) reported third-quarter earnings per share of $1.33, well above the Zacks Consensus Estimate of $1.20 and the year-earlier figure of $1.09. Excluding the impact of stock-based compensation expense, third quarter 2010 earnings came in at $1.35 per share. Performance was boosted by higher revenues and lower share count. Revenues increased 5% to $1.18 billion, with Tysabri and Rituxan being the primary growth drivers. Revenues were slightly above the Zacks Consensus Estimate of $1.16 billion. Revenue by Major Products Third quarter Tysabri revenues came in at $221 million, up 7% from the prior period. Global in-market net sales of Tysabri, which is partnered with Elan Corp. (ELN), came in at $307 million (up 9%) in the third quarter of 2010. Tysabri global sales consisted of US sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/26/biib-biogen-beats-earnings-forecast-by-a-wide-margin/56648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Delivered Earnings Surprises Over the Past Few Quarters</title>
		<link>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-delivered-earnings-surprises-over-the-past-few-quarters/56422</link>
		<comments>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-delivered-earnings-surprises-over-the-past-few-quarters/56422#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:43:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56422</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) is slated to announce its third quarter results on October 26. The Zacks Consensus Estimate is $1.20, well above the year-earlier earnings of $1.09. Second Quarter Highlights Biogen Idec Inc. reported second-quarter earnings per share of $1.27, well above the Zacks Consensus Estimate of $1.08 and the year-earlier figure of $0.73. Performance was boosted by higher revenues. Revenues increased 11% to $1.2 billion, with Tysabri and Rituxan being the primary growth drivers. Second quarter Tysabri revenues came in at $219 million, up 17% from the prior period. Global in-market net sales of Tysabri, which is partnered with Elan Corp. (ELN), came in at $298 million (up 17%) in the second quarter of 2010. Despite carrying a black-box warning for the risk of progressive multifocal leukoencephalopathy (PML) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-delivered-earnings-surprises-over-the-past-few-quarters/56422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Roche Holdings Amend Deal</title>
		<link>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-and-roche-holdings-amend-deal/56325</link>
		<comments>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-and-roche-holdings-amend-deal/56325#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:40:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56325</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) and Roche Holdings Ltd. (RHHBY) recently announced that they amended their deal related to antibodies targeting CD20. The agreement covers products like Rituxan (rituximab) approved for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphoid leukemia (CLL), and rheumatoid arthritis (RA), ocrelizumab in mid-stage trails for multiple sclerosis (MS) and GA101 in late stage trials for NHL and CLL. Per the amended agreement, Roche will now be responsible for the development and commercialization of ocrelizumab. Biogen will receive tiered, double-digit royalties on the US sales of the drug. The companies have also decided that the commercialization of ocrelizumab will not affect their current profit-sharing arrangement for Rituxan. Moreover, Biogen’s share of profit/loss associated with the US development and commercialization of GA101 has been increased to 35% from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-and-roche-holdings-amend-deal/56325/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Presents Encouraging Data on MS Drug</title>
		<link>http://www.stockbloghub.com/2010/10/18/sny-sanofi-aventis-presents-encouraging-data-on-ms-drug/55600</link>
		<comments>http://www.stockbloghub.com/2010/10/18/sny-sanofi-aventis-presents-encouraging-data-on-ms-drug/55600#comments</comments>
		<pubDate>Tue, 19 Oct 2010 05:05:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55600</guid>
		<description><![CDATA[French pharmaceutical company, Sanofi-Aventis (SNY) recently presented encouraging results on its multiple sclerosis (MS) candidate, teriflunomide. Results from a phase III randomized, double-blind, placebo-controlled study (TEMSO) showed that teriflunomide helped reduce annualized relapse rates by 31% compared to placebo. The study evaluated two doses of teriflunomide – 7 mg and 14 mg. Sanofi said that treatment with teriflunomide helped reduce the risk of disability progression by 30% and 24% for the 14 mg and 7 mg doses, respectively. The candidate was found to be well-tolerated. Sanofi also presented long-term safety data on relapsing multiple sclerosis patients. Eight years follow-up data from a phase II study showed that the candidate was well-tolerated. The successful development of teriflunomide could provide multiple sclerosis patients with a new first-line treatment option. Teriflunomide is currently ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/18/sny-sanofi-aventis-presents-encouraging-data-on-ms-drug/55600/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Cuts Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305</link>
		<comments>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305#comments</comments>
		<pubDate>Thu, 07 Oct 2010 23:28:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54305</guid>
		<description><![CDATA[We are downgrading Cell Therapeutics, Inc. (CTIC) to Underperform from Neutral with a price target of $0.25 primarily due to the uncertainty surrounding the US approval of its lead candidate, pixantrone. Pixantrone (proposed trade name: Pixuvri), is currently under development for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. Cell Therapeutics Inc., based in Seattle, Washington, is focused on developing drugs for cancer. The company received a setback in April 2010, when the US Food and Drug Administration (FDA) denied approval to pixantrone and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone. In August ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Analyst Reduces Share Rating to Neutral</title>
		<link>http://www.stockbloghub.com/2010/10/03/biib-biogen-idec-analyst-reduces-share-rating-to-neutral/53721</link>
		<comments>http://www.stockbloghub.com/2010/10/03/biib-biogen-idec-analyst-reduces-share-rating-to-neutral/53721#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:07:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53721</guid>
		<description><![CDATA[We recently downgraded Biogen Idec, Inc. (BIIB) to Neutral from our previous Outperform recommendation. Biogen is one of the world’s largest biotechnology companies. Its main areas of focus include neurology, oncology, hemophilia and immunology. Products such as Avonex (for multiple sclerosis), Rituxan (for non-Hodgkin’s lymphoma), and Tysabri (for multiple sclerosis) currently drive the top line. Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,322.9 million, up 5.5%, in 2009. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continued to see an increase ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/biib-biogen-idec-analyst-reduces-share-rating-to-neutral/53721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG Earns FDA Approval of Oral Multiple Sclerosis Drug</title>
		<link>http://www.stockbloghub.com/2010/10/02/nvs-novartis-ag-earns-fda-approval-of-oral-multiple-sclerosis-drug/52657</link>
		<comments>http://www.stockbloghub.com/2010/10/02/nvs-novartis-ag-earns-fda-approval-of-oral-multiple-sclerosis-drug/52657#comments</comments>
		<pubDate>Sat, 02 Oct 2010 22:05:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52657</guid>
		<description><![CDATA[Novartis AG (NVS) received a huge boost recently with the US Food and Drug Administration (FDA) approving its oral multiple sclerosis (MS) drug, Gilenya. Gilenya is the first oral treatment to gain US approval for the first-line treatment of relapsing forms of MS. The drug is shown to significantly reduce relapse rates and delay disability progression. The FDA approved Novartis’ drug along with a Risk Evaluation and Mitigation Strategy (REMS) which will inform patients and physicians on the safe use and risks associated with the drug. The FDA has recommended that patients should be monitored for a decrease in heart rate on starting treatment with Gilenya. The drug has also been seen to increase the risk of infections. The agency also recommended ophthalmologic evaluation as instances of serious eye problems ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/02/nvs-novartis-ag-earns-fda-approval-of-oral-multiple-sclerosis-drug/52657/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Awards Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978</link>
		<comments>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978#comments</comments>
		<pubDate>Fri, 10 Sep 2010 06:05:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50978</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alnylam Pharmaceuticals (ALNY) with a target price of $15. Alnylam, founded in 2002 and headquartered in Cambridge, Massachusetts, focuses on developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam’s founders pioneered the discovery of RNAi, and the company is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Key programs in the areas of respiratory syncytial virus (RSV), Parkinson’s disease (PD), cystic fibrosis (CF) and spinal cord injury round out the company’s core focus. Alnylam generates revenues from research collaborations, grants and licensing of the RNAi technology outside its core focus area. Alnylam has partnerships with several large pharmaceutical companies, such as Novartis (NVS), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Strikes $345 Million Licensing Deal to Develop Treatment For Lou Gehrig’s Disease</title>
		<link>http://www.stockbloghub.com/2010/08/23/biib-biogen-strikes-345-million-licensing-deal-to-develop-treatment-for-lou-gehrig%e2%80%99s-disease/48615</link>
		<comments>http://www.stockbloghub.com/2010/08/23/biib-biogen-strikes-345-million-licensing-deal-to-develop-treatment-for-lou-gehrig%e2%80%99s-disease/48615#comments</comments>
		<pubDate>Mon, 23 Aug 2010 14:09:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48615</guid>
		<description><![CDATA[Biogen Idec (BIIB) recently entered into an exclusive licensing agreement with Knopp Neurosciences for the development and commercialization of KNS-760704 for the treatment of amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease and other potential indications. Deal worth more than $345 million Per the terms of the deal, Knopp stands to receive up to $345 million from Biogen in addition to royalties. The payments include an upfront amount of $20 million and $60 million for the purchase of Knopp stock. Besides this, Biogen could make additional milestone payments of up to $265 million which will become due on the achievement of development, regulatory, and sales targets. Knopp will also be entitled to receive tiered, double-digit royalties on worldwide sales. While Biogen will be responsible for the development and worldwide commercialization ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/23/biib-biogen-strikes-345-million-licensing-deal-to-develop-treatment-for-lou-gehrig%e2%80%99s-disease/48615/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price</title>
		<link>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443</link>
		<comments>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:16:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48443</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249</link>
		<comments>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249#comments</comments>
		<pubDate>Wed, 18 Aug 2010 14:01:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48249</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2010/08/06/biib-biogen-idec-bull-of-the-day/46917</link>
		<comments>http://www.stockbloghub.com/2010/08/06/biib-biogen-idec-bull-of-the-day/46917#comments</comments>
		<pubDate>Fri, 06 Aug 2010 16:53:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46917</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported second-quarter earnings per share of $1.27, well above the year-ago figure of $0.73 and the Zacks Consensus Estimate of $1.08. Revenue increased 11% to $1.2 billion, with Tysabri and Rituxan being the primary growth drivers. Based on second quarter results and Biogen&#8217;s new guidance for 2010, we have raised our earnings estimate for 2010 by 29 cents to $4.73. Key products Avonex and Tysabri continue to contribute significantly to sales and we expect Biogen to maintain its leading position in the multiple sclerosis market. The company is working on building its pipeline through acquisitions and in-licensing deals. In our opinion, Biogen has the best pipeline in all of biotech, and could be an attractive takeover candidate for pharma companies interested in biologics. Although we remain concerned ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/biib-biogen-idec-bull-of-the-day/46917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals&#8217; Second Quarter Loss Down on Lower Costs</title>
		<link>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791</link>
		<comments>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791#comments</comments>
		<pubDate>Thu, 05 Aug 2010 17:22:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46791</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc.’s (ALNY) second-quarter net loss of 35 cents per share was 20 cents below the loss per share in the second quarter of 2009. The Zacks Consensus Estimate indicated a loss of 30 cents per share for the reported quarter. The narrower year-over-year loss in the second quarter of 2010 was primarily attributable to the lower spend on research and development during the quarter. Revenues for the reported quarter climbed 8% to $26.6 million slightly above the Zacks Consensus Revenue Estimate of $26 million. Revenues were inclusive of $14 million from the company’s alliance with Roche HLDG LTD(RHHBY), $5.5 million from Alnylam‘s partnership with Takeda Pharmaceuticals, $1.9 million in revenues from license fee from Regulus Therapeutics Inc. pertaining to the partnership with Sanofi-Aventis (SNY), in addition to $5.2 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

